TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Vasić, Novak
AU  - Cerne, Darko
AU  - Kos, Janko
AU  - Bogavac-Stanojević, Nataša
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3338
AB  - Background: Cathepsin S (CTSS) is a cysteine protease involved in atherogenesis. We compared the plasma CTSS as well as other biomarkers of atherosclerosis in patients with abdominal aortic aneurysms (AAA) and aortoiliac occlusive disease (AOD), aiming to identify the underlying pathogenic mechanisms of the disease development. Also, we hypothesised that the level of plasma CTSS simultaneously increases with a decrease of plasma high-density lipoprotein cholesterol (HDL-C) values. Methods: 33 patients with AAA and 34 patients with AOD were included in this study. Results: There was no difference in the level of plasma CTSS between the two analysed groups (p=0.833). In the patients with AAA, the plasma CTSS was correlated with HDL-C (r = -0.377, p = 0.034) and total bilirubin (r = 0.500, p = 0.003) while, unexpectedly, it was not correlated with cystatin C (Cys C) (r = 0.083, p = 0.652). In the patients with AOD, the plasma CTSS correlated with triglycerides (r = 0.597, p  lt  0.001), only. When the patients were divided according to HDL-C (with HDL-C  lt = 0.90 and HDL-C >0.90 mmol/L), the plasma CTSS values differed among these groups (31.27 vs.25.61 mu g/L, respectively, p lt 0.001). Conclusions: These results provide the first evidence that CTSS negatively correlated with HDL-C and bilirubin in patients with AAA. It is possible that differences in the association of the CTSS and other markers of atherosclerosis can determine whether atherosclerotic aorta will develop dilatation or stenosis.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Plasma cathepsin S is associated with high-density lipoprotein cholesterol and bilirubin in patients with abdominal aortic aneurysms
VL  - 38
IS  - 3
SP  - 268
EP  - 275
DO  - 10.2478/jomb-2018-0039
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Vasić, Novak and Cerne, Darko and Kos, Janko and Bogavac-Stanojević, Nataša",
year = "2019",
abstract = "Background: Cathepsin S (CTSS) is a cysteine protease involved in atherogenesis. We compared the plasma CTSS as well as other biomarkers of atherosclerosis in patients with abdominal aortic aneurysms (AAA) and aortoiliac occlusive disease (AOD), aiming to identify the underlying pathogenic mechanisms of the disease development. Also, we hypothesised that the level of plasma CTSS simultaneously increases with a decrease of plasma high-density lipoprotein cholesterol (HDL-C) values. Methods: 33 patients with AAA and 34 patients with AOD were included in this study. Results: There was no difference in the level of plasma CTSS between the two analysed groups (p=0.833). In the patients with AAA, the plasma CTSS was correlated with HDL-C (r = -0.377, p = 0.034) and total bilirubin (r = 0.500, p = 0.003) while, unexpectedly, it was not correlated with cystatin C (Cys C) (r = 0.083, p = 0.652). In the patients with AOD, the plasma CTSS correlated with triglycerides (r = 0.597, p  lt  0.001), only. When the patients were divided according to HDL-C (with HDL-C  lt = 0.90 and HDL-C >0.90 mmol/L), the plasma CTSS values differed among these groups (31.27 vs.25.61 mu g/L, respectively, p lt 0.001). Conclusions: These results provide the first evidence that CTSS negatively correlated with HDL-C and bilirubin in patients with AAA. It is possible that differences in the association of the CTSS and other markers of atherosclerosis can determine whether atherosclerotic aorta will develop dilatation or stenosis.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Plasma cathepsin S is associated with high-density lipoprotein cholesterol and bilirubin in patients with abdominal aortic aneurysms",
volume = "38",
number = "3",
pages = "268-275",
doi = "10.2478/jomb-2018-0039"
}

Mirjanić-Azarić, B., Vasić, N., Cerne, D., Kos, J.,& Bogavac-Stanojević, N.. (2019). Plasma cathepsin S is associated with high-density lipoprotein cholesterol and bilirubin in patients with abdominal aortic aneurysms. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 268-275.
https://doi.org/10.2478/jomb-2018-0039

Mirjanić-Azarić B, Vasić N, Cerne D, Kos J, Bogavac-Stanojević N. Plasma cathepsin S is associated with high-density lipoprotein cholesterol and bilirubin in patients with abdominal aortic aneurysms. in Journal of Medical Biochemistry. 2019;38(3):268-275.
doi:10.2478/jomb-2018-0039 .

Mirjanić-Azarić, Bosa, Vasić, Novak, Cerne, Darko, Kos, Janko, Bogavac-Stanojević, Nataša, "Plasma cathepsin S is associated with high-density lipoprotein cholesterol and bilirubin in patients with abdominal aortic aneurysms" in Journal of Medical Biochemistry, 38, no. 3 (2019):268-275,
https://doi.org/10.2478/jomb-2018-0039 . .

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Kotur-Stevuljević, Jelena
AU  - Cerne, Darko
AU  - Zupan, Janja
AU  - Marc, Janja
AU  - Vujić, Zorica
AU  - Crevar-Sakač, Milkica
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Radenković, Miroslav
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3189
AB  - Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Pharmaceutical Biology
T1  - The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet
VL  - 56
IS  - 1
SP  - 138
EP  - 144
DO  - 10.1080/13880209.2018.1434549
ER  - 

@article{
author = "Bogavac-Stanojević, Nataša and Kotur-Stevuljević, Jelena and Cerne, Darko and Zupan, Janja and Marc, Janja and Vujić, Zorica and Crevar-Sakač, Milkica and Sopić, Miron and Munjas, Jelena and Radenković, Miroslav and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Pharmaceutical Biology",
title = "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet",
volume = "56",
number = "1",
pages = "138-144",
doi = "10.1080/13880209.2018.1434549"
}

Bogavac-Stanojević, N., Kotur-Stevuljević, J., Cerne, D., Zupan, J., Marc, J., Vujić, Z., Crevar-Sakač, M., Sopić, M., Munjas, J., Radenković, M.,& Jelić-Ivanović, Z.. (2018). The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology
Taylor & Francis Ltd, Abingdon., 56(1), 138-144.
https://doi.org/10.1080/13880209.2018.1434549

Bogavac-Stanojević N, Kotur-Stevuljević J, Cerne D, Zupan J, Marc J, Vujić Z, Crevar-Sakač M, Sopić M, Munjas J, Radenković M, Jelić-Ivanović Z. The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology. 2018;56(1):138-144.
doi:10.1080/13880209.2018.1434549 .

Bogavac-Stanojević, Nataša, Kotur-Stevuljević, Jelena, Cerne, Darko, Zupan, Janja, Marc, Janja, Vujić, Zorica, Crevar-Sakač, Milkica, Sopić, Miron, Munjas, Jelena, Radenković, Miroslav, Jelić-Ivanović, Zorana, "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet" in Pharmaceutical Biology, 56, no. 1 (2018):138-144,
https://doi.org/10.1080/13880209.2018.1434549 . .

TY  - JOUR
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Simić-Ogrizović, Sanja
AU  - Vekić, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Cerne, Darko
AU  - Kocbek, Petra
AU  - Marc, Janja
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3085
AB  - Some cardiovascular complications in patients with chronic kidney disease and end-stage renal disease may be caused by structurally and functionally modified lipoproteins. Redox status (advanced oxidation protein products [AOPPs]), prooxidant-antioxidant balance, total protein sulfhydryl (SH-groups), and paraoxonase 1 (PON1) activity were assessed in 77 renal patients and 20 controls. Lipoproteins were isolated using ultracentrifugation. PON1, PON3, and pentraxin-3 concentration were determined by enzyme-linked immunosorbent assay (ELISA). Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as a sum of dyslipidemia, oxidative stress, and inflammation scores. The dyslipidemia score (P  lt  .001), oxy score (P  lt  .01), inflammation score (P  lt  .001), and the DOI score (P  lt  .001) were higher in patient groups compared with controls. The very-low-density lipoprotein (VLDL) fraction contained the highest amount of AOPP (P  lt  .001) compared with other lipoprotein fractions in all groups. The low-density lipoprotein (LDL) fraction contained elevated AOPP in all groups compared with the high-density lipoprotein (HDL) fraction (P  lt  .001). Significant positive correlation was observed between AOPP in LDL fraction and DOI score (rho = 0.510, P  lt  .01). Dyslipidemia, oxidative stress, and inflammation play an interactive role in renal disease and are mutually associated with redox status in VLDL, LDL, and HDL lipoproteins in plasma of renal patients.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease
VL  - 69
IS  - 10
SP  - 861
EP  - 870
DO  - 10.1177/0003319718780041
ER  - 

@article{
author = "Miljković, Milica and Stefanović, Aleksandra and Simić-Ogrizović, Sanja and Vekić, Jelena and Bogavac-Stanojević, Nataša and Cerne, Darko and Kocbek, Petra and Marc, Janja and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena",
year = "2018",
abstract = "Some cardiovascular complications in patients with chronic kidney disease and end-stage renal disease may be caused by structurally and functionally modified lipoproteins. Redox status (advanced oxidation protein products [AOPPs]), prooxidant-antioxidant balance, total protein sulfhydryl (SH-groups), and paraoxonase 1 (PON1) activity were assessed in 77 renal patients and 20 controls. Lipoproteins were isolated using ultracentrifugation. PON1, PON3, and pentraxin-3 concentration were determined by enzyme-linked immunosorbent assay (ELISA). Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as a sum of dyslipidemia, oxidative stress, and inflammation scores. The dyslipidemia score (P  lt  .001), oxy score (P  lt  .01), inflammation score (P  lt  .001), and the DOI score (P  lt  .001) were higher in patient groups compared with controls. The very-low-density lipoprotein (VLDL) fraction contained the highest amount of AOPP (P  lt  .001) compared with other lipoprotein fractions in all groups. The low-density lipoprotein (LDL) fraction contained elevated AOPP in all groups compared with the high-density lipoprotein (HDL) fraction (P  lt  .001). Significant positive correlation was observed between AOPP in LDL fraction and DOI score (rho = 0.510, P  lt  .01). Dyslipidemia, oxidative stress, and inflammation play an interactive role in renal disease and are mutually associated with redox status in VLDL, LDL, and HDL lipoproteins in plasma of renal patients.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease",
volume = "69",
number = "10",
pages = "861-870",
doi = "10.1177/0003319718780041"
}

Miljković, M., Stefanović, A., Simić-Ogrizović, S., Vekić, J., Bogavac-Stanojević, N., Cerne, D., Kocbek, P., Marc, J., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Kotur-Stevuljević, J.. (2018). Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. in Angiology
Sage Publications Inc, Thousand Oaks., 69(10), 861-870.
https://doi.org/10.1177/0003319718780041

Miljković M, Stefanović A, Simić-Ogrizović S, Vekić J, Bogavac-Stanojević N, Cerne D, Kocbek P, Marc J, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. in Angiology. 2018;69(10):861-870.
doi:10.1177/0003319718780041 .

Miljković, Milica, Stefanović, Aleksandra, Simić-Ogrizović, Sanja, Vekić, Jelena, Bogavac-Stanojević, Nataša, Cerne, Darko, Kocbek, Petra, Marc, Janja, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, "Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease" in Angiology, 69, no. 10 (2018):861-870,
https://doi.org/10.1177/0003319718780041 . .

TY  - JOUR
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Gojković, Tamara
AU  - Simić-Ogrizović, Sanja
AU  - Bogavac-Stanojević, Nataša
AU  - Cerne, Darko
AU  - Ilić, Jasmina
AU  - Stefanović, Ivan
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3067
AB  - Introduction: Cardiovascular complications, as the main cause of mortality in renal patients, are followed with altered lipoproteins composition. Considering that paraoxonase-1 (PON1) is an anti-oxidative enzyme located mainly on HDL particles, the current study has aim to investigate whether failure of kidney function leads to changes in the distribution of PON1 activity between different HDL subclasses. Materials and methods: In 77 renal patients (21 chronic kidney disease (CKD) and 56 end stage renal disease (ESRD) patients on dialysis) and 20 healthy subjects PON1 activity on HDL2 and HDL3 subclasses was determined by zymogram method that combines gradient gel electrophoresis separation of HDL subclasses and measurement of PON1 activity in the same gel. Results: Serum paraoxonase (p  lt  0.01) and arylesterase activity (p  lt  0.001) of PON1 as well as its concentration (p  lt  0.01) were significantly lower in CKD and ESRD patients compared to controls. Relative proportion of HDL3 subclasses was higher in ESRD patients than in healthy participants, while HDL2 subclasses was significantly decreased in CKD (p  lt  0.05) and ESRD (p  lt  0.001) patients, as compared to controls. Furthermore, control subjects had higher PON1 activity on HDL2 (CKD and ESRD patients p  lt  0.001) and HDL3 (CKD p  lt  0.05; ESRD patients p  lt  0.001) subclasses in comparison with the both patients groups. Also, significant negative correlation was found between paraoxonase activity of PON1 in serum and creatinine concentration (rho = -0.373, p  lt  0.01). Conclusions: This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease
VL  - 60
SP  - 52
EP  - 58
DO  - 10.1016/j.clinbiochem.2018.08.006
ER  - 

@article{
author = "Miljković, Milica and Stefanović, Aleksandra and Vekić, Jelena and Zeljković, Aleksandra and Gojković, Tamara and Simić-Ogrizović, Sanja and Bogavac-Stanojević, Nataša and Cerne, Darko and Ilić, Jasmina and Stefanović, Ivan and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena",
year = "2018",
abstract = "Introduction: Cardiovascular complications, as the main cause of mortality in renal patients, are followed with altered lipoproteins composition. Considering that paraoxonase-1 (PON1) is an anti-oxidative enzyme located mainly on HDL particles, the current study has aim to investigate whether failure of kidney function leads to changes in the distribution of PON1 activity between different HDL subclasses. Materials and methods: In 77 renal patients (21 chronic kidney disease (CKD) and 56 end stage renal disease (ESRD) patients on dialysis) and 20 healthy subjects PON1 activity on HDL2 and HDL3 subclasses was determined by zymogram method that combines gradient gel electrophoresis separation of HDL subclasses and measurement of PON1 activity in the same gel. Results: Serum paraoxonase (p  lt  0.01) and arylesterase activity (p  lt  0.001) of PON1 as well as its concentration (p  lt  0.01) were significantly lower in CKD and ESRD patients compared to controls. Relative proportion of HDL3 subclasses was higher in ESRD patients than in healthy participants, while HDL2 subclasses was significantly decreased in CKD (p  lt  0.05) and ESRD (p  lt  0.001) patients, as compared to controls. Furthermore, control subjects had higher PON1 activity on HDL2 (CKD and ESRD patients p  lt  0.001) and HDL3 (CKD p  lt  0.05; ESRD patients p  lt  0.001) subclasses in comparison with the both patients groups. Also, significant negative correlation was found between paraoxonase activity of PON1 in serum and creatinine concentration (rho = -0.373, p  lt  0.01). Conclusions: This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease",
volume = "60",
pages = "52-58",
doi = "10.1016/j.clinbiochem.2018.08.006"
}

Miljković, M., Stefanović, A., Vekić, J., Zeljković, A., Gojković, T., Simić-Ogrizović, S., Bogavac-Stanojević, N., Cerne, D., Ilić, J., Stefanović, I., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Kotur-Stevuljević, J.. (2018). Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 60, 52-58.
https://doi.org/10.1016/j.clinbiochem.2018.08.006

Miljković M, Stefanović A, Vekić J, Zeljković A, Gojković T, Simić-Ogrizović S, Bogavac-Stanojević N, Cerne D, Ilić J, Stefanović I, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. in Clinical Biochemistry. 2018;60:52-58.
doi:10.1016/j.clinbiochem.2018.08.006 .

Miljković, Milica, Stefanović, Aleksandra, Vekić, Jelena, Zeljković, Aleksandra, Gojković, Tamara, Simić-Ogrizović, Sanja, Bogavac-Stanojević, Nataša, Cerne, Darko, Ilić, Jasmina, Stefanović, Ivan, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, "Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease" in Clinical Biochemistry, 60 (2018):52-58,
https://doi.org/10.1016/j.clinbiochem.2018.08.006 . .

TY  - CONF
AU  - Mirjanić-Azarić, Bosa
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Juergens, Guenter
AU  - Cerne, Darko
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2829
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina
VL  - 263
SP  - e213
EP  - e214
DO  - 10.1016/j.atherosclerosis.2017.06.694
ER  - 

@conference{
author = "Mirjanić-Azarić, Bosa and Zeljković, Aleksandra and Vekić, Jelena and Juergens, Guenter and Cerne, Darko",
year = "2017",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina",
volume = "263",
pages = "e213-e214",
doi = "10.1016/j.atherosclerosis.2017.06.694"
}

Mirjanić-Azarić, B., Zeljković, A., Vekić, J., Juergens, G.,& Cerne, D.. (2017). Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 263, e213-e214.
https://doi.org/10.1016/j.atherosclerosis.2017.06.694

Mirjanić-Azarić B, Zeljković A, Vekić J, Juergens G, Cerne D. Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina. in Atherosclerosis. 2017;263:e213-e214.
doi:10.1016/j.atherosclerosis.2017.06.694 .

Mirjanić-Azarić, Bosa, Zeljković, Aleksandra, Vekić, Jelena, Juergens, Guenter, Cerne, Darko, "Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina" in Atherosclerosis, 263 (2017):e213-e214,
https://doi.org/10.1016/j.atherosclerosis.2017.06.694 . .

TY  - CONF
AU  - Miljković, Milica
AU  - Kotur-Stevuljević, Jelena
AU  - Stefanović, Aleksandra
AU  - Simić-Ogrizović, Sanja
AU  - Bogavac-Stanojević, Nataša
AU  - Cerne, Darko
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2928
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease
VL  - 263
SP  - e190
EP  - e190
DO  - 10.1016/j.atherosclerosis.2017.06.609
ER  - 

@conference{
author = "Miljković, Milica and Kotur-Stevuljević, Jelena and Stefanović, Aleksandra and Simić-Ogrizović, Sanja and Bogavac-Stanojević, Nataša and Cerne, Darko and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2017",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease",
volume = "263",
pages = "e190-e190",
doi = "10.1016/j.atherosclerosis.2017.06.609"
}

Miljković, M., Kotur-Stevuljević, J., Stefanović, A., Simić-Ogrizović, S., Bogavac-Stanojević, N., Cerne, D., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2017). Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 263, e190-e190.
https://doi.org/10.1016/j.atherosclerosis.2017.06.609

Miljković M, Kotur-Stevuljević J, Stefanović A, Simić-Ogrizović S, Bogavac-Stanojević N, Cerne D, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease. in Atherosclerosis. 2017;263:e190-e190.
doi:10.1016/j.atherosclerosis.2017.06.609 .

Miljković, Milica, Kotur-Stevuljević, Jelena, Stefanović, Aleksandra, Simić-Ogrizović, Sanja, Bogavac-Stanojević, Nataša, Cerne, Darko, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease" in Atherosclerosis, 263 (2017):e190-e190,
https://doi.org/10.1016/j.atherosclerosis.2017.06.609 . .

TY  - JOUR
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Simić-Ogrizović, Sanja
AU  - Dumić, Jerka
AU  - Cerne, Darko
AU  - Jelić-Ivanović, Zorana
AU  - Kotur-Stevuljević, Jelena
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2886
AB  - Inflammation, apoptosis and extracellular remodeling play significant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p lt 0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p lt 0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p lt 0.01 and p lt 0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular filtration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular filtration rate can discriminate renal patients with high and low risk of a coronary event.
PB  - Sestre Milosrdnice Univ Hospital, Zagreb
T2  - Acta Clinica Croatica
T1  - Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients
VL  - 56
IS  - 4
SP  - 673
EP  - 680
DO  - 10.20471/acc.2017.56.04.14
ER  - 

@article{
author = "Miljković, Milica and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Simić-Ogrizović, Sanja and Dumić, Jerka and Cerne, Darko and Jelić-Ivanović, Zorana and Kotur-Stevuljević, Jelena",
year = "2017",
abstract = "Inflammation, apoptosis and extracellular remodeling play significant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p lt 0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p lt 0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p lt 0.01 and p lt 0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular filtration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular filtration rate can discriminate renal patients with high and low risk of a coronary event.",
publisher = "Sestre Milosrdnice Univ Hospital, Zagreb",
journal = "Acta Clinica Croatica",
title = "Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients",
volume = "56",
number = "4",
pages = "673-680",
doi = "10.20471/acc.2017.56.04.14"
}

Miljković, M., Stefanović, A., Bogavac-Stanojević, N., Simić-Ogrizović, S., Dumić, J., Cerne, D., Jelić-Ivanović, Z.,& Kotur-Stevuljević, J.. (2017). Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients. in Acta Clinica Croatica
Sestre Milosrdnice Univ Hospital, Zagreb., 56(4), 673-680.
https://doi.org/10.20471/acc.2017.56.04.14

Miljković M, Stefanović A, Bogavac-Stanojević N, Simić-Ogrizović S, Dumić J, Cerne D, Jelić-Ivanović Z, Kotur-Stevuljević J. Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients. in Acta Clinica Croatica. 2017;56(4):673-680.
doi:10.20471/acc.2017.56.04.14 .

Miljković, Milica, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Simić-Ogrizović, Sanja, Dumić, Jerka, Cerne, Darko, Jelić-Ivanović, Zorana, Kotur-Stevuljević, Jelena, "Association of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patients" in Acta Clinica Croatica, 56, no. 4 (2017):673-680,
https://doi.org/10.20471/acc.2017.56.04.14 . .

TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Juergens, Guenther
AU  - Milivojac, Tatjana
AU  - Avram, Sanja
AU  - Ćorić, Jozo
AU  - Marc, Janja
AU  - Černe, Darko
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2432
AB  - Background: High-density lipoproteins (HDL) have atheroprotective biological properties: antioxidative, anti-apoptotic, anti-inflammatory, and they have the efflux capacity of cellular cholesterol. Plasma mRNA analysis can be used to investigate statin pleiotropy in vivo as a new analytical tool for non-invasive assessment of gene expression in vascular beds. The aim of this study was to assess the pleiotropic effects of atorvastatin in stable angina patients with highrisk values (group A) as compared with patients who had borderline and desirable HDL-cholesterol (HDL-C) values (group B). Methods: The atorvastatin therapy (20 mg/day) was given to forty-three patients with stable angina for 10 weeks. We investigated three statin pleiotropy-targeted genes: intercellular adhesion molecule-1, chemokine (C-C motif) ligand 2 and cathepsin S and assessed by gel electrophoresis gradient the effects of atorvastatin on HDL size and subclasses. Results: In group A, after therapy, HDL-C concentration was significantly increased but not in group B. Atorvastatin lowered plasma chemokine (C-C motif) ligand 2 and intercellular adhesion molecule-1 mRNA levels in both groups, but did not change the plasma cathepsin S mRNA levels. In group A only, baseline total bilirubin showed negative cor relations with the genes of cathepsin S (r=-0.506; p = 0.023) and significantly increased after therapy. Conclusions: HDL-C and bilirubin can be promising therapeutic targets in the treatment of cardiovascular diseases. Analysis of cell-free mRNA in plasma might become a useful tool for estimating statin pleiotropy.
AB  - Uvod: Lipoproteini velike gustine (HDL) imaju ateroprotektivne biološke osobine: antioksidativne, antiapoptotičke, antiinflamatorne kao i kapacitet da izvlače holesterol iz ćelija. Analiza plazmatske mRNA može da se koristi za ispitivanje plejotropnih efekata statina in vivo kao novo analitičko sredstvo za neinvazivnu procenu ekspresije gena u zidu krvnog suda. Cilj ove studije je bio da se procene plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom sa visokorizičnim vrednostima (grupa A) u odnosu na pacijente sa graničnim i poželjnim vrednostima HDL holesterola (HDLC) (grupa B). Metode: Četrdeset tri pacijenta sa stabilnom anginom su primala terapiju atorvastatinom (20 mg/dan) 10 nedelja. Mi smo ispitivali tri gena značajna za plejotropno delovanje statina: intracelularni adhezioni molekul-1, hemokin (C-C motiv) ligand 2 i katepsin S i procenjivali smo efekte atorvastatina na veličinu i raspodelu HDL subfrakcija pomoću elektroforeze na poliakrilamidnom gradijent gelu. Rezultati: U grupi A, posle terapije, HDL-C koncentracija se značajno povećala, ali ne i u grupi B. Atorvastatin je snizio plazmatski nivo hemokin (C-C motiv) liganda 2 i intracelularnog adhezionog molekula-1 mRNA u obe grupe, ali nije promenio plazmatski nivo gena za katepsin S. Samo u grupi A, ukupni bilirubin je pokazao negativnu korelaciju sa genom za katepsin S (r = -0,506; p = 0,023) pre započinjanja terapije i značajni porast nakon terapije atorvastatinom. Zaključak: HDL-C i bilirubin mogu biti obećavajući terapijski ciljevi u lečenju kardiovaskularnih bolesti. Analiza slobodne mRNA (eng. cell-free mRNA) u plazmi može postati korisno sredstvo za procenu plejotropnog delovanja statina.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA
T1  - Plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom - dokazi dobijeni analizom veličine i raspodele subfrakcija lipoproteina velike gustine i plazmatske mRNA
VL  - 34
IS  - 3
SP  - 314
EP  - 322
DO  - 10.2478/jomb-2014-0058
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Jelić-Ivanović, Zorana and Zeljković, Aleksandra and Vekić, Jelena and Juergens, Guenther and Milivojac, Tatjana and Avram, Sanja and Ćorić, Jozo and Marc, Janja and Černe, Darko",
year = "2015",
abstract = "Background: High-density lipoproteins (HDL) have atheroprotective biological properties: antioxidative, anti-apoptotic, anti-inflammatory, and they have the efflux capacity of cellular cholesterol. Plasma mRNA analysis can be used to investigate statin pleiotropy in vivo as a new analytical tool for non-invasive assessment of gene expression in vascular beds. The aim of this study was to assess the pleiotropic effects of atorvastatin in stable angina patients with highrisk values (group A) as compared with patients who had borderline and desirable HDL-cholesterol (HDL-C) values (group B). Methods: The atorvastatin therapy (20 mg/day) was given to forty-three patients with stable angina for 10 weeks. We investigated three statin pleiotropy-targeted genes: intercellular adhesion molecule-1, chemokine (C-C motif) ligand 2 and cathepsin S and assessed by gel electrophoresis gradient the effects of atorvastatin on HDL size and subclasses. Results: In group A, after therapy, HDL-C concentration was significantly increased but not in group B. Atorvastatin lowered plasma chemokine (C-C motif) ligand 2 and intercellular adhesion molecule-1 mRNA levels in both groups, but did not change the plasma cathepsin S mRNA levels. In group A only, baseline total bilirubin showed negative cor relations with the genes of cathepsin S (r=-0.506; p = 0.023) and significantly increased after therapy. Conclusions: HDL-C and bilirubin can be promising therapeutic targets in the treatment of cardiovascular diseases. Analysis of cell-free mRNA in plasma might become a useful tool for estimating statin pleiotropy., Uvod: Lipoproteini velike gustine (HDL) imaju ateroprotektivne biološke osobine: antioksidativne, antiapoptotičke, antiinflamatorne kao i kapacitet da izvlače holesterol iz ćelija. Analiza plazmatske mRNA može da se koristi za ispitivanje plejotropnih efekata statina in vivo kao novo analitičko sredstvo za neinvazivnu procenu ekspresije gena u zidu krvnog suda. Cilj ove studije je bio da se procene plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom sa visokorizičnim vrednostima (grupa A) u odnosu na pacijente sa graničnim i poželjnim vrednostima HDL holesterola (HDLC) (grupa B). Metode: Četrdeset tri pacijenta sa stabilnom anginom su primala terapiju atorvastatinom (20 mg/dan) 10 nedelja. Mi smo ispitivali tri gena značajna za plejotropno delovanje statina: intracelularni adhezioni molekul-1, hemokin (C-C motiv) ligand 2 i katepsin S i procenjivali smo efekte atorvastatina na veličinu i raspodelu HDL subfrakcija pomoću elektroforeze na poliakrilamidnom gradijent gelu. Rezultati: U grupi A, posle terapije, HDL-C koncentracija se značajno povećala, ali ne i u grupi B. Atorvastatin je snizio plazmatski nivo hemokin (C-C motiv) liganda 2 i intracelularnog adhezionog molekula-1 mRNA u obe grupe, ali nije promenio plazmatski nivo gena za katepsin S. Samo u grupi A, ukupni bilirubin je pokazao negativnu korelaciju sa genom za katepsin S (r = -0,506; p = 0,023) pre započinjanja terapije i značajni porast nakon terapije atorvastatinom. Zaključak: HDL-C i bilirubin mogu biti obećavajući terapijski ciljevi u lečenju kardiovaskularnih bolesti. Analiza slobodne mRNA (eng. cell-free mRNA) u plazmi može postati korisno sredstvo za procenu plejotropnog delovanja statina.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA, Plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom - dokazi dobijeni analizom veličine i raspodele subfrakcija lipoproteina velike gustine i plazmatske mRNA",
volume = "34",
number = "3",
pages = "314-322",
doi = "10.2478/jomb-2014-0058"
}

Mirjanić-Azarić, B., Jelić-Ivanović, Z., Zeljković, A., Vekić, J., Juergens, G., Milivojac, T., Avram, S., Ćorić, J., Marc, J.,& Černe, D.. (2015). The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 34(3), 314-322.
https://doi.org/10.2478/jomb-2014-0058

Mirjanić-Azarić B, Jelić-Ivanović Z, Zeljković A, Vekić J, Juergens G, Milivojac T, Avram S, Ćorić J, Marc J, Černe D. The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. in Journal of Medical Biochemistry. 2015;34(3):314-322.
doi:10.2478/jomb-2014-0058 .

Mirjanić-Azarić, Bosa, Jelić-Ivanović, Zorana, Zeljković, Aleksandra, Vekić, Jelena, Juergens, Guenther, Milivojac, Tatjana, Avram, Sanja, Ćorić, Jozo, Marc, Janja, Černe, Darko, "The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA" in Journal of Medical Biochemistry, 34, no. 3 (2015):314-322,
https://doi.org/10.2478/jomb-2014-0058 . .

TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Đerić, Mirjana
AU  - Milivojac, Tatjana
AU  - Fonović, Ursa Pecar
AU  - Marc, Janja
AU  - Kos, Janko
AU  - Cerne, Darko
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2069
AB  - Aim: We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant LDL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSS-lowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of  lt = 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated.
PB  - Japan Atherosclerosis Soc, Tokyo
T2  - Journal of Atherosclerosis and Thrombosis
T1  - Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients
VL  - 21
IS  - 8
SP  - 868
EP  - 877
DO  - 10.5551/jat.21410
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Vekić, Jelena and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Đerić, Mirjana and Milivojac, Tatjana and Fonović, Ursa Pecar and Marc, Janja and Kos, Janko and Cerne, Darko",
year = "2014",
abstract = "Aim: We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant LDL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSS-lowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of  lt = 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated.",
publisher = "Japan Atherosclerosis Soc, Tokyo",
journal = "Journal of Atherosclerosis and Thrombosis",
title = "Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients",
volume = "21",
number = "8",
pages = "868-877",
doi = "10.5551/jat.21410"
}

Mirjanić-Azarić, B., Vekić, J., Zeljković, A., Jelić-Ivanović, Z., Đerić, M., Milivojac, T., Fonović, U. P., Marc, J., Kos, J.,& Cerne, D.. (2014). Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients. in Journal of Atherosclerosis and Thrombosis
Japan Atherosclerosis Soc, Tokyo., 21(8), 868-877.
https://doi.org/10.5551/jat.21410

Mirjanić-Azarić B, Vekić J, Zeljković A, Jelić-Ivanović Z, Đerić M, Milivojac T, Fonović UP, Marc J, Kos J, Cerne D. Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients. in Journal of Atherosclerosis and Thrombosis. 2014;21(8):868-877.
doi:10.5551/jat.21410 .

Mirjanić-Azarić, Bosa, Vekić, Jelena, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Đerić, Mirjana, Milivojac, Tatjana, Fonović, Ursa Pecar, Marc, Janja, Kos, Janko, Cerne, Darko, "Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients" in Journal of Atherosclerosis and Thrombosis, 21, no. 8 (2014):868-877,
https://doi.org/10.5551/jat.21410 . .